China
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor (I) Fusion Protein (8MW0511) will be presented orally and as a poster respectively at ESMO Congress 2023.
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct clinical trial of its second generation pan-TRK inhibitor zurletrectinib (ICP-723) to treat pediatric patients (2 to 12 years old) in China.
RemeGen’s Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren’s Syndrome: Findings Published in Prestigious Rheumatology Journal
RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has announced that their Phase II clinical study of telitacicept (RC18) for the treatment of Primary Sjögren's Syndrome (pSS) in adults has been published in top international medical journal Rheumatology.
Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection at the 12th International AIDS Society (IAS) Conference on HIV Science in Brisbane, Australia, and virtually.
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product.
对话高盛国际CEO：继续在中国投资，专注长期愿景
The CEO of Goldman Sachs announced it will continue to invest in China to move forward side by side with clients.
国家医保局公布《谈判药品续约规则》
The National Medical Insurance Administration of China announced Negotiating Drug Contract Renewal Rules.
US Plans Narrow China Tech Investment Limits, Likely by 2024
The Biden administration’s plans to restrict investments in China will be narrowly focused on cutting-edge technology and only new investments.
China issues draft to ease rules on foreign investment in asset management firms
China issues draft to ease rules on foreign investment in asset management firms.
Healthcare-focused investment firm Vertex Ventures HC launches $200m Fund III
Vertex Ventures HC (VVHC) has launched a $200 million Fund III to support life sciences and medical technology companies.
